cabozantinib,atezolizumab
exelixis,roche
['atezolizumab', 'sclc', 'nsclc', 'cabozantinib', 'cosmic-021', 'exelixis', 'exelixisinc']
 presents results from cohorts 7 and 20 of the cosmic-021 study: cabozantinib (c) plus atezolizumab (a) or c alone in patients with ansclc previously treated with an immune checkpoint inhibitor. today at 1 pm in hall d1 #asco22
Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements